
Corcept Therapeutics Incorporated
NASDAQ•CORT
CEO: Dr. Joseph K. Belanoff M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2004-04-14
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
Contact Information
Market Cap
$3.65B
P/E (TTM)
34.2
38.2
Dividend Yield
--
52W High
$117.33
52W Low
$32.99
52W Range
Rank20Top 6.4%
6.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$207.64M+13.75%
4-Quarter Trend
EPS
$0.19-57.78%
4-Quarter Trend
FCF
$54.48M-24.54%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Product Revenue Growth Strong Net revenue $559.3M (9M 2025), driven by 39.0% volume increase for Korlym products despite price decreases.
Relacorilant NDA PDUFA Set Relacorilant NDA PDUFA date set for December 30, 2025, for endogenous hypercortisolism treatment indication.
Investing Cash Flow Reverses Investing activities provided $81.6M cash (9M 2025), reversing $113.2M used in the comparable prior nine-month period.
Stock Repurchase Activity High Financing cash use totaled $189.2M (9M 2025), including $172.9M spent on the ongoing common stock repurchase program.
Risk Factors
Net Income Significantly Lower Net income attributable to stockholders $74.3M (9M 2025), down from $109.3M (2024), reflecting increased operating expenses.
SG&A Expenses Increased SG&A expense reached $318.5M (9M 2025), substantially higher than $196.9M (2024) supporting commercialization efforts.
Generic Litigation Appeal Pending Teva generic launched January 2024; appeal pending after District Court ruled against Korlym patent infringement claims.
R&D Failure Risk Remains Clinical development is lengthy and expensive; failure to demonstrate safety or efficacy prevents commercialization of candidates.
Outlook
Ovarian Cancer NDA Review Ovarian cancer combination therapy NDA PDUFA date set for July 11, 2026, based on positive ROSELLA trial results.
R&D Spending Expected Higher Expect R&D expense to be higher in 2025 than 2024 as clinical programs advance and new trials are initiated.
ALS Pivotal Trial Planned Plan to initiate pivotal Phase 3 trial for Dazucorilant as a treatment for patients suffering from Amyotrophic Lateral Sclerosis in 2026.
Sufficient Liquidity Expected Current cash and securities position is expected to fund operations and planned R&D activities over the next 12 months.
Peer Comparison
Revenue (TTM)
JAZZ$4.16B
HALO$1.24B
CORT$741.17M
Gross Margin (Latest Quarter)
CORT97.8%
MRUS94.7%
AXSM93.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| RVMD | $23.25B | -23.7 | -49.2% | 7.0% |
| JAZZ | $10.29B | -27.9 | -9.3% | 47.8% |
| AXSM | $8.94B | -38.6 | -357.2% | 32.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.5%
Moderate Growth
4Q Net Income CAGR
-14.0%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Feb 25, 2026
EPS:$0.27
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 4, 2025|Revenue: $207.64M+13.7%|EPS: $0.19-57.8%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 31, 2025|Revenue: $194.43M+18.7%|EPS: $0.33-2.9%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 5, 2025|Revenue: $157.21M+7.1%|EPS: $0.19-29.6%MeetForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 26, 2025|Revenue: $675.04M+39.9%|EPS: $1.35+32.4%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 30, 2024|Revenue: $182.55M+47.7%|EPS: $0.45+45.2%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 29, 2024|Revenue: $163.80M+39.1%|EPS: $0.34+25.9%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 1, 2024|Revenue: $146.81M+39.0%|EPS: $0.27+80.0%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 15, 2024|Revenue: $482.38M+20.0%|EPS: $1.02+7.4%Beat